Sophiris Will Start Phase III For Topsalysin In Prostate Cancer Despite Mixed Data Package
Executive Summary
Emphasizing solid results for the first administration of topsalysin in patients with localized prostate cancer, the firm is sticking with Phase III plans for one dose despite final Phase IIb data showing no clinical benefit from a second dose. Sophiris’ share price tumbled on the news.
You may also be interested in...
Dark Cloud Lifts On Sophiris Bio's Localized Prostate Cancer Injectable Topsalysin
Phase IIb study death after intratumoral injection was unrelated to study drug, San Diego-based start-up says.
Patient Death Obscures Efficacy Success For Sophiris’ Intratumoral Prostate Cancer Therapy
The bad outweighed the good for Sophiris on a day in which it unveiled promising Phase IIb data for topsalysin, but also took a huge stock hit with news of a patient death in the trial.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.